Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Peptide hormone]

S Ohnami1, S Ohnami, I Adachi

  • 1Common Laboratory, National Cancer Center Research Institute.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Peptide hormones show promise as tumor markers for endocrine tumors. ProGRP is a specific marker for small cell lung carcinoma (SCLC), aiding early detection and prognosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Search for B→X_{s}νν[over ¯] Decays.

Physical review letters·2026
Same author

Search for Feebly Interacting Particles in B Decays with Missing Energy at Belle.

Physical review letters·2026
Same author

Search for B^{0}→K^{*0}τ^{+}τ^{-} Decays at the Belle II Experiment.

Physical review letters·2025
Same author

Search for a Dark Higgs Boson Produced in Association with Inelastic Dark Matter at the Belle II Experiment.

Physical review letters·2025
Same author

Study of χ_{bJ}(2P)→ωϒ(1S) at Belle.

Physical review letters·2025
Same author

Search for Lepton-Flavor-Violating Decay Modes B^{0}→K_{S}^{0}τ^{±}ℓ^{∓} with Hadronic B Tagging at Belle and Belle II.

Physical review letters·2025
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Peptide hormones are established tumor markers for endocrine tumors.
  • Limited specificity and low serum concentrations hinder their routine use in many cancers, including ectopic hormone-producing tumors.
  • The RET proto-oncogene is implicated in multiple endocrine neoplasia (MEN) syndromes.

Purpose of the Study:

  • To evaluate the clinical utility of ProGRP as a serum tumor marker for small cell lung carcinoma (SCLC).
  • To explore the potential of combined peptide hormone and molecular genetic markers for endocrine tumor diagnosis.

Main Methods:

  • Clinical validation of ProGRP as a serum tumor marker.
  • Review of the role of the RET proto-oncogene in MEN syndromes.

Related Experiment Videos

Main Results:

  • ProGRP demonstrates specificity and reliability as a serum tumor marker for SCLC.
  • ProGRP aids in early SCLC detection and prognosis evaluation.
  • The RET proto-oncogene is identified as a key gene in MEN 2A and 2B.

Conclusions:

  • ProGRP is a valuable tumor marker for SCLC.
  • Future diagnostic strategies for endocrine tumors may integrate serum peptide hormone and molecular genetic markers.